Therapeutic Solutions International, Inc. (TSOI) announced the granting of a patent covering the ability of QuadraMune and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers.
Therapeutic Solutions International, Inc.
Equities
TSOI
US8833781011
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | -12.50% |
|
-22.22% | -30.00% |
1st Jan change | Capi. | |
---|---|---|
-30.00% | 3.25M | |
+16.43% | 133B | |
-7.55% | 10.99B | |
-12.07% | 7.66B | |
+42.65% | 5.71B | |
-20.18% | 4.82B | |
+8.48% | 3.44B | |
-20.37% | 2.45B | |
-18.39% | 1.91B | |
-16.75% | 1.85B |
- Stock Market
- Equities
- TSOI Stock
- News Therapeutic Solutions International, Inc.
- Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients